U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.50%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.54%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.59%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.41%)
     
  • BTC-USD

    19,279.02
    -142.43 (-0.73%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Athira Pharma Shares Fall To 52-Week Low - Read Why

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Athira Pharma Inc (NASDAQ: ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease (AD).

  • The study did not meet the primary endpoint of a statistically significant change in ERP P300 Latency for the modified intent to treat (mITT) population when compared with placebo at 26 weeks in a pooled analysis of the 40 mg and 70 mg dose groups.

  • Secondary endpoints, including ADAS-Cog11, ADCS-CGIC, and ADCS-ADL23, were not significant in treated subjects compared with placebo at 26 weeks. Pre-specified subgroup analysis identified a potential diminished effect of the combination of standard-of-care (AChEIs) and fosgonimeton. Other subgroup analyses did not show differences between groups, including dose, disease severity, and APOE genotype.

  • A post hoc analysis showed a potentially beneficial change in ERP P300 compared to placebo at 26 weeks and cognitive improvement as measured by ADAS-Cog11 (-3.3 points) compared with placebo at 26 weeks.

  • Fosgonimeton was generally well tolerated, with a favorable safety profile. No treatment-related Serious Adverse Events or deaths were observed in the study.

  • Price Action: ATHA shares are down 65.1% at $2.95 during the premarket session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.